PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
Compare
ARA-290 vs TB-500
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
ARA-290
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
4
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
TB-500
103 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 38% · Mixed 62% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
219
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
70
Fatigue
65
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
14
0.025–0.05 mg
1
0.1–0.2 mg
1
0.2–0.4 mg
29
0.4–0.6 mg
25
0.6–1 mg
2
1–2 mg
5
2–3 mg
72
3–5 mg
45
5+ mg
25
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 63 days · Based on 40 repeat reporters
Sources (10)
Published sources linked on the ARA-290 and TB-500 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014
- Wiki study page →Source
PubMed
The time to develop treatments for diabetic neuropathy
Rendell MS. Expert opinion on investigational drugs. 2021
- Wiki study page →Source
PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
- Wiki study page →Source
PubMed
Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart
Smart N, Riley PR. Ann N Y Acad Sci. 2012
- Wiki study page →Source
ClinicalTrials.gov
Thymosin beta-4 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012
- Wiki study page →Source
PubMed
Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing
Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007
- Wiki study page →Source
PubMed
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026
- Wiki study page →Source
PubMed
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026